|Systematic (IUPAC) name|
|Pregnancy cat.||C for Intranasal|
|Legal status||POM (UK) ℞-only (US)|
|Mol. mass||538.576 g/mol|
Fluticasone furoate is a synthetic corticosteroid derived from fluticasone, marketed by GlaxoSmithKline as Veramyst (US) and Avamys (Australia, Canada, EU, South Africa, Mexico, and Israel) for the treatment of allergic rhinitis. It is marketed under the name "Furamist" in India by Cipla. In India it is also marketed by Dr Reddys under the trade name 'Ennhale'. It can be administered by a nasal spray.
The combination drug fluticasone furoate/vilanterol is approved for use in the United States by the Food and Drug Administration for long-term maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and emphysema.
- Fluticasone propionate
- Fluticasone furoate/vilanterol
- Anti-inflammatory uses of glucocorticoids
- Bruni FM, De Luca G, Venturoli V, Boner AL (2009). "Intranasal corticosteroids and adrenal suppression". Neuroimmunomodulation 16 (5): 353–62. doi:10.1159/000216193. PMID 19571596.
- "FDA approves Breo Ellipta to treat chronic obstructive pulmonary disease". Food and Drug Administration. May 10, 2013.
|This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it.|